baohuoside-i and Diabetic-Cardiomyopathies

Icariside II is a flavonoid extracted from Epimedium that has antioxidant, anti‑inflammatory and antiapoptotic effects. The aim of the present study was to evaluate the effects icariside II on diabetic cardiomyopathy in streptozotocin-induced diabetic rats. Icariside II treatment improved body weight, heart/body weight ratio and fasting blood glucose in diabetic model rats. Icariside II was demonstrated to reduce the expression levels of creatine kinase and lactate dehydrogenase in serum, and to lower cardiac oxidative stress, inflammation and apoptosis levels in diabetic rats. Icariside II treatment induced phosphoinositide 3‑kinase and phosphorylated‑Akt expression, and suppressed inducible nitric oxide synthase (iNOS) and nuclear factor (NF)‑κB protein expression in diabetic rat. Results from the present study suggested that treatment with icariside II improved diabetic cardiomyopathy in streptozotocin‑induced diabetic rats by activating the Akt/NOS/NF‑κB pathway.

Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Creatine Kinase; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Epimedium; Fasting; Flavonoids; Gene Expression Regulation; Hypoglycemic Agents; L-Lactate Dehydrogenase; Male; NF-kappa B; Nitric Oxide Synthase Type II; Organ Size; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Signal Transduction; Streptozocin